SCHEMBL2230303

SCHEMBL2230303

C/C(=N\c1ccccc1F)c1cccc(/C(C)=N/c2ccccc2F)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
AGTR1 P30556 3/20 0.38
PKM P14618 1/20 0.38
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.35
MAPK1 P28482 2/20 0.35
USP2 O75604 1/20 0.35
MAPT P10636 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KMT2A Q03164 4/20 0.33
GAA P10253 3/20 0.33
MEN1 O00255 3/20 0.33
HTT P42858 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA9 Q16790 1/20 0.33
HSP90AA1 P07900 1/20 0.33
TDP1 Q9NUW8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2230306 1.00 NPC1 (0.38) NPC1RAB9AAGTR1PKMKDM4E
Hydrochloric Acid SCHEMBL3295936 0.97 NPC1 (0.40) NPC1RAB9AAGTR1PKMKDM4E
Hydrochloric Acid SCHEMBL3295940 0.97 NPC1 (0.40) NPC1RAB9AAGTR1PKMKDM4E
Hydrochloric Acid SCHEMBL14632794 0.97 RAB9A (0.37) NPC1RAB9AAGTR1PKMKDM4E
SCHEMBL5352634 0.86 PAX8 (0.32) NPC1RAB9AAGTR1PKMKDM4E
SCHEMBL6877976 0.86 PAX8 (0.32) NPC1RAB9AAGTR1PKMKDM4E
SCHEMBL1685488 0.81 KDM4E (0.34) NPC1RAB9AAGTR1PKMKDM4E
SCHEMBL1685486 0.81 KDM4E (0.34) NPC1RAB9AAGTR1PKMKDM4E
SCHEMBL23457658 0.81 ALDH1A1 (0.36) NPC1RAB9AAGTR1KDM4ESMN1; SMN2
SCHEMBL23457659 0.81 ALDH1A1 (0.36) NPC1RAB9AAGTR1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011089000-A1 PROCESS FOR THE PREPARATION OF ETHYLENE COPOLYMER COMPOSITIONS IN THE PRESENCE OF AN OLIGOMERIZATION CATALYST BASELL POLYOLEFINE GMBH (DE) 2011-07-28 WO disclosed
US-7528091-B2 Magnesium-containing carrier component and application to olefin polymerization MITSUI CHEMICALS, INC. (JP) 2009-05-05 US disclosed
EP-1943281-A1 HYBRID CATALYST SYSTEMS SUPPORTED ON MAGNESIUM HALIDE Basell Polyolefine GmbH (DE) 2008-07-16 EP disclosed
US-20080015401-A1 Magnesium-containing carrier component and application to olefin polymerization NAKAYAMA YASUSHI 2008-01-17 US disclosed
US-7253132-B2 Magnesium-containing carrier components and application thereof to olefin polymerization MITSUI CHEMICALS, INC. (JP) 2007-08-07 US disclosed
WO-2007042252-A1 HYBRID CATALYST SYSTEMS SUPPORTED ON MAGNESIUM HALIDE BASELL POLYOLEFINE GMBH (DE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015401-A1 Magnesium-containing carrier component and application to olefin polymerization OSBP, COG6, OSBP2 NPC1 200/4885RAB9A 4228/4885AGTR1 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.